<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Pharmaceutical law</title>
    <subTitle>regulation of research, development, and marketing</subTitle>
  </titleInfo>
  <name type="personal">
    <namePart>Clark, Michael E.</namePart>
    <namePart type="date">1956-</namePart>
  </name>
  <name type="corporate">
    <namePart>American Bar Association</namePart>
    <namePart>Health Law Section.</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">vau</placeTerm>
    </place>
    <place>
      <placeTerm type="text">Arlington, Va</placeTerm>
    </place>
    <publisher>Bureau of National Affairs</publisher>
    <dateIssued>c2007</dateIssued>
    <dateIssued encoding="marc">2007</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
    <extent>xlvi, 853 p. 26 cm.</extent>
  </physicalDescription>
  <tableOfContents>Statutory and regulatory controls for drug development -- Key federal agencies regulating pharmaceuticals -- Federal regulation of advertising, promotion, and distribution practices -- Potential liability for drug companies, health care providers and insurers: off-label prescribing and internet advertising -- Federal regulation of clinical research -- Avoiding fraud and abuse penalties and sanctions -- Regulation of privacy under hipaa and other privacy laws -- Federal sentencing guidelines and compliance measures -- The FDA approval process for new drugs -- State regulatory schemes for pharmaceuticals and related issues -- Antitrust and intellectual law issues for pharmaceutical companies -- Securities law issues and disclosure considerations for pharmaceutical companies.</tableOfContents>
  <note type="statement of responsibility">editor-in-chief, Michael E. Clark.</note>
  <note>"American Bar Association, Health Law Section"</note>
  <note>Includes bibliographical references and index.</note>
  <subject authority="lcsh">
    <topic>Pharmacy</topic>
    <topic>Law and legislation</topic>
    <geographic>United States</geographic>
  </subject>
  <subject authority="lcsh">
    <topic>Drug development</topic>
    <geographic>United States</geographic>
  </subject>
  <subject authority="lcsh">
    <topic>Pharmaceutical Industry</topic>
    <geographic>United States</geographic>
  </subject>
  <subject authority="lcsh">
    <topic>Drugs</topic>
    <topic>Law and legislation</topic>
    <geographic>United States</geographic>
  </subject>
  <classification authority="lcc">KF 2915 .P4 P495 2007</classification>
  <identifier type="isbn">9781570185762 (alk. paper)</identifier>
  <identifier type="isbn">157018576X (alk. paper)</identifier>
  <identifier type="lccn">2007033206</identifier>
  <recordInfo>
    <recordContentSource authority="marcorg">PUCPR</recordContentSource>
    <recordCreationDate encoding="marc">070810</recordCreationDate>
    <recordChangeDate encoding="iso8601">20160527201727.0</recordChangeDate>
    <recordIdentifier source="OCoLC">288234</recordIdentifier>
  </recordInfo>
</mods>
